Vertex announces advancements of Suzetrigine in acute and neuropathic pain
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Breakthrough Therapy designation for pain associated with DPN granted by FDA
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
A game changing solution for the pharmaceutical industry
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Subscribe To Our Newsletter & Stay Updated